English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In recent years, the spectrum of anti-Purkinje cell autoimmunity has widened to include novel clinico-immunologic entities, a number of which have been associated with antibodies targeting intracellular antigens (protein kinase C gamma (PKCγ), carbonic anhydrase–related protein (CARP VIII), Ca/Rho GTPase activating protein 26 (ARHGAP26), inositol 1,4,5-trisphosphate receptor 1 (ITPR1), and HOMER3).1–3 Anti-ITPR1 belong to this group of newly discovered anticerebellar autoantibodies,4 but little is known regarding the exact clinical and paraclinical phenotypes associated with these antibodies and their potential association with cancer.

Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies